FDA nods nivolumab with ipilimumab as first line treatment of metastatic non-small cell lung cancer

Bristol Myers Squibb announced that Opdivo (nivolumab) 3 mg/kg plus Yervoy (ipilimumab) 1 mg/kg (injections for intravenous use) was approved by the U.S. Food and Drug Administration (FDA) for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors express PD-L1 (≥1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations.

source https://www.pharmatutor.org/pharma-news/2020/fda-nods-nivolumab-with-ipilimumab-as-first-line-treatment-of-metastatic-non-small-cell-lung-cancer